BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
Date: September 24, 2019
Company: BioVie Inc. (Nevada Corporation)
Event: Entry into a Material Definitive Agreement and unregistered sale of equity securities.
The Company entered into a Securities Purchase Agreement with Acuitas Group Holdings, LLC ("Acuitas") to secure financing and modify existing investor rights in anticipation of a planned public offering (Form S-1).
Key Financial Metrics and Transaction Details
- Debt Instrument: 10% OID Convertible Delayed Draw Debenture with an aggregate commitment of up to $2.0 million.
- Initial Draw: $500,000 funded upon execution.
- Future Draws: Three potential tranches of $500,000 each, available on October 15, November 15, and December 15, 2019.
- Interest and Accrual: Debenture accrues additional principal at 6% per annum and interest at 10% per annum.
- Equity Issuance:
- 140,625,000 shares of Class A Common Stock ("Commitment Shares").
- 140,625,000 warrants ("Commitment Warrants") to purchase an equal number of shares.
- 15,625,000 additional warrants ("Bridge Warrants") issued for the initial draw.
- Conversion/Exercise Price: $0.032 per share, or the lower of $0.032 or 80% of the public offering price upon the closing of the Public Offering.
- Redemption: Mandatorily redeemable upon the closing of the Public Offering at 100% of accrued principal and unpaid interest.
Material Changes and Rights Modifications
The agreement modifies Acuitas's rights under a prior July 3, 2018 agreement:
- Waiver of Adjustments: Acuitas waived rights to a 50% adjustment of the purchase price of Preferred Stock, warrant exercise prices, and purchase option prices triggered by reductions in intellectual property useful life.
- Condition for Waiver: The waiver is conditioned on the listing of Common Stock on NASDAQ or raising $2.0 million in additional funds by November 30, 2019.
- Ownership Floor: If underwriters exercise an over-allotment option and Acuitas's beneficial ownership falls below 60% (fully diluted), the Company must issue additional shares and warrants to restore Acuitas's ownership to 60%.
Outlook, Risks, and Contingencies
- Public Offering Dependency: Key terms, including conversion prices and mandatory redemption, are contingent on the closing of a planned Public Offering.
- Reverse Stock Split: Warrant exercisability is tied to the effectiveness of a pending reverse stock split or December 1, 2019.
- Liquidity Risk: Future funding tranches are delayed draw, meaning capital is not immediately available without further action.
- Dilution Risk: Significant issuance of shares and warrants (over 334 million shares and warrants total expected upon closing) may result in substantial dilution to existing shareholders.
Investor Verification Checklist
- Verify the status and expected closing date of the Form S-1 Registration Statement (File No. 333-231136).
- Confirm the effectiveness of the pending reverse stock split to determine warrant exercisability dates.
- Assess the Company's ability to meet the November 30, 2019 deadline for NASDAQ listing or raising $2.0 million to validate the waiver of price adjustments.
- Review the fully diluted share count to understand the impact of the 60% ownership floor provision for Acuitas.
- Check for any subsequent draws on the Debenture after the initial $500,000.